WST · West Pharmaceutical Services Inc
$349.42
+3.26 (+0.94%)
At close · Aug 14
Market Cap
$24.83B
Shares
70.38M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.07B
+6.3%
FY2025
Net Income
$493.7M
+0.2%
FY2025
Gross Margin
35.91%
+1.4pp
FY2025
Operating Margin
19.03%
-0.7pp
FY2025
Diluted EPS
$6.79
+1.5%
FY2025
Operating Cash Flow
$754.8M
+15.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.33B | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B | $2.15B | $1.84B | $1.72B | $1.6B | $1.51B | $1.4B | $1.42B | $1.37B | $1.27B | $1.19B | $1.1B | $1.06B | $1.05B | |
| $2.1B | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B | $1.38B | $1.23B | $1.17B | $1.09B | $1.01B | $944M | $973.6M | $933.7M | $878.7M | $853M | $786.6M | $752.1M | $748.5M | |
| $1.22B | $1.1B | $998.5M | $1.13B | $1.14B | $1.18B | $767.8M | $605.7M | $545.4M | $512.9M | $501.4M | $455.8M | $447.8M | $434.7M | $387.7M | $339.3M | $318.1M | $303.6M | $302.6M | |
| — | 35.91% | 34.51% | 38.28% | 39.36% | 41.52% | 35.76% | 32.92% | 31.76% | 32.07% | 33.23% | 32.56% | 31.5% | 31.77% | 30.61% | 28.46% | 28.8% | 28.76% | 28.79% | |
| $74.4M | $74.3M | $69.1M | $68.4M | $58.5M | $52.8M | $46.9M | $38.9M | $40.3M | $39.1M | $36.8M | $34.1M | $37.3M | $37.9M | $33.2M | $29.1M | $23.9M | $19.9M | $18.7M | |
| $426.8M | $393.6M | $338.5M | $353.4M | $316.9M | $362.8M | $302M | $272.7M | $262.9M | $246M | $239.6M | $233M | $228.7M | $234.9M | $218.1M | $191.1M | $187.7M | $177.7M | $159.3M | |
| — | $2.8M | $3.6M | $3.6M | $3.7M | $5.4M | $4.4M | $3.4M | $2.7M | $2.4M | $2.6M | $3.5M | $4.9M | $3.9M | $3.9M | $4.3M | $4.1M | — | — | |
| $181.4M | $171.4M | $155.4M | $137.3M | $120.6M | $122.3M | $109.1M | $103.4M | $104.4M | $96.7M | $90.7M | $89.9M | $90M | $85.2M | $76.9M | $75.7M | $73.2M | $68.1M | — | |
| — | — | — | — | — | — | — | — | — | — | $26.4M | — | — | — | $2.1M | $5.3M | — | — | — | |
| $680.4M | $584.9M | $569.9M | $676M | $734M | $752.3M | $406.9M | $296.6M | $240.3M | $225.8M | $195.2M | $128.6M | $182M | $162.4M | $135.1M | $109.6M | $90.7M | $97.5M | $124.1M | |
| — | 19.03% | 19.7% | 22.92% | 25.43% | 26.57% | 18.95% | 16.12% | 13.99% | 14.12% | 12.93% | 9.19% | 12.8% | 11.87% | 10.67% | 9.19% | 8.21% | 9.24% | 11.81% | |
| $861.8M | $756.3M | $725.3M | $813.3M | $854.6M | $874.6M | $516M | $400M | $344.7M | $322.5M | $285.9M | $218.5M | $272M | $247.6M | $212M | $185.3M | $163.9M | $165.6M | — | |
| $4.5M | $500K | $3M | $9M | $7.9M | $8.2M | $8.2M | $8.5M | $8.4M | $7.8M | $8.1M | $14.1M | $16.5M | $17M | $16.7M | $18.2M | $16.8M | $15.2M | $16M | |
| -$1M | -$1M | -$1M | $22M | -$54.1M | -$3.4M | -$5.6M | -$4.8M | $400K | $3.1M | $1.6M | — | — | — | — | $4.2M | -$100K | -$200K | — | |
| $15.5M | $14.4M | $14.7M | $17.7M | $20.7M | $20.1M | $17.4M | $8.9M | $7.6M | $9.2M | $8.2M | $5.8M | $5.3M | $5.4M | $4.8M | $6.3M | $4.4M | $3M | $800K | |
| — | — | — | -$4.3M | -$3.5M | -$4.3M | -$2.5M | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| $693.6M | $600.9M | $585.5M | $698M | $679.9M | $748.9M | $401.3M | $291.8M | $240.7M | $222.4M | $189.8M | $116.1M | $169M | $147.1M | $108.6M | $92.7M | $74.5M | $83.1M | $109.5M | |
| $144.2M | $121.6M | $107.5M | $122.3M | $114.7M | $107.2M | $72.5M | $59M | $41.4M | $80.9M | $54.4M | $26.3M | $47.2M | $40.2M | $32.7M | $23.5M | $13.6M | $13.5M | $23.7M | |
| $564.9M | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M | $346.2M | $241.7M | $206.9M | $150.7M | $143.6M | $95.6M | $127.1M | $112.3M | $80.7M | $75.5M | $65.3M | $72.6M | $86M | |
| — | 16.06% | 17.03% | 20.12% | 20.3% | 23.37% | 16.13% | 13.14% | 12.05% | 9.42% | 9.52% | 6.83% | 8.94% | 8.21% | 6.37% | 6.33% | 5.91% | 6.88% | 8.18% | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $600K | |
| $513.2M | $646.3M | $378.4M | $632.6M | $562.5M | $612.8M | $385.2M | $246.3M | $170M | — | — | — | — | — | — | — | $53.7M | $97.8M | $7.5M | |
| USD/shares | — | $6.83 | $6.75 | $7.98 | $7.87 | $8.89 | $4.68 | $3.27 | $2.80 | $2.04 | $1.96 | $1.33 | $1.79 | $1.61 | $1.19 | $1.12 | $1.96 | $2.21 | $2.65 |
| USD/shares | — | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 | $1.30 | $1.75 | $1.57 | $1.15 | $1.08 | $1.89 | $2.12 | $2.50 |
| shares | — | 72.3M | 73M | 74.3M | 74.4M | 74.4M | 73.9M | 74M | 73.9M | 73.9M | 73.3M | 72M | 70.9M | 69.6M | 68.1M | 67.3M | 33.3M | 32.8M | 32.4M |
| shares | — | 72.7M | 73.7M | 75.3M | 75.8M | 76.3M | 75.8M | 75.4M | 75.4M | 75.8M | 75M | 73.8M | 72.8M | 71.4M | 71.8M | 74M | 36.7M | 36.3M | 36.1M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2025: $1.89B in buybacks, $689.4M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
7.39×
Peer median 2.75×
EV/EBIT
36.15×
Peer median 28.46×
P/E (TTM)
45.17×
Peer median 34.46×
Peer medians compare against the 19 similar-size Medical Instruments & Supplies companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $2,492,100,000 | $2,334,500,000 | $2,397,300,000 | $2,406,800,000 | $2,317,300,000 | $1,648,600,000 | $1,398,600,000 | $1,308,600,000 |
| Contract Manufactured Products | $582,000,000 | $558,700,000 | $552,500,000 | $480,400,000 | $514,700,000 | $498,600,000 | $441,500,000 | $409,100,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $1,329,600,000 | $1,230,800,000 | $1,238,500,000 | $1,286,500,000 | $1,198,000,000 | $975,600,000 | $814,700,000 | $766,100,000 |
| Other Europe Countries | $451,000,000 | $385,500,000 | $388,100,000 | $359,200,000 | $341,300,000 | $236,800,000 | $251,100,000 | $230,500,000 |
| Germany | $380,300,000 | $372,500,000 | $406,100,000 | $398,700,000 | $474,300,000 | $282,100,000 | $236,300,000 | $235,900,000 |
| Other Countries | $353,300,000 | $339,000,000 | $348,500,000 | $364,300,000 | $357,400,000 | $253,700,000 | $213,400,000 | $201,800,000 |
| Ireland | $333,300,000 | $323,200,000 | $285,700,000 | $240,300,000 | $247,600,000 | $226,000,000 | $173,800,000 | $138,100,000 |
| France | $226,600,000 | $242,200,000 | $282,900,000 | $237,900,000 | $213,000,000 | $172,700,000 | $150,600,000 | $145,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $657,200,000 | $577,800,000 | $710,100,000 | $784,400,000 | $796,100,000 | $434,500,000 | $313,600,000 | $266,400,000 |
| Contract Manufactured Products | $63,400,000 | $72,300,000 | $72,100,000 | $60,400,000 | $67,200,000 | $68,600,000 | $49,100,000 | $44,300,000 |
| Corporate and Eliminations | — | — | — | — | — | — | -$66,100,000 | -$70,400,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Proprietary Products | 26.4% | 24.8% | 29.6% | 32.6% | 34.4% | 26.4% | 22.4% | 20.4% |
| Contract Manufactured Products | 10.9% | 12.9% | 13% | 12.6% | 13.1% | 13.8% | 11.1% | 10.8% |